Cautionary Note on Forward-looking Statements

This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Cautionary Note on Non-GAAP Financial Measures

This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
Championing global health equity

Martin Fitchet, M.D.
Global Head, Global Public Health
## Major gaps remain in achieving global health equity

In low- and middle-income countries (LMICs), limited resources and infrastructure challenges impact access to innovative medicines and other medical technologies.

<table>
<thead>
<tr>
<th>2 billion people globally have no access to modern medicines(^1)</th>
<th>4–7-year lag between approval of new innovations in high-income countries and access in LMICs(^2)</th>
<th>2/3 of the world’s population does not have access to safe surgery(^3)</th>
</tr>
</thead>
</table>

### Research and development is limited for diseases primarily impacting populations in LMICs (e.g., Tuberculosis, HIV, Neglected Tropical Diseases)

- 0.2% of grants for biomedical research are awarded to LMICs\(^4\)
- Less than 20% of clinical trials are conducted in these geographies\(^5\)
- 95% of TB deaths occur in LMICs\(^6\)

---

\(^1\) Access to Medicine Foundation
\(^2\) PLOS One, 2016; JAMA Network, 2021
\(^3\) The Lancet Commission, Global Surgery 2030
\(^4\) World Health Organization
\(^5\) International Journal for Equity in Health, 2018
\(^6\) Johnson & Johnson
We work to overcome barriers to access in almost 100 LMICs through industry-first approaches such as equity-based tiered pricing and our Global Public Health (GPH) model.

*Reports through Janssen Research & Development
At the core of our efforts is a focus on tackling some of the most pressing healthcare challenges impacting LMICs.

### Outsmarting Epidemics
- MDR-TB
- HIV
- COVID-19
- Ebola

### Beating Neglected Tropical Diseases
- Intestinal Worms
- Leprosy
- Dengue

### Tackling NCDs and Global Surgery
- Serious Mental Illness
- Long Bone Fracture
- Obstetric Fistula

MDR-TB = Multidrug-Resistant Tuberculosis  
NCDs = Non-Communicable Diseases
Outsmarting Epidemics

70% of all Johnson & Johnson COVID-19 vaccines were shipped to LMICs; the most-used vaccine in Africa

459,000 courses of our MDR-TB medicine delivered since launch

233,000 fully-vaccinated with Ebola vaccine regimen

MDR-TB = Multidrug-Resistant Tuberculosis

Johnson & Johnson
Beating NTDs

Intestinal Worms
>2 billion doses of our medicine for intestinal worms donated since 2006

Dengue
Early-stage compound in development which may potentially treat dengue and provide protection against acquiring dengue

Leprosy
Anticipate primary completion of proof-of-concept Phase 2 trial to assess treatment for leprosy in early 2023
65,000 healthcare workers have been trained as part of work with the Rwandan government to address serious mental illness as part of a holistic approach.

5 billion¹ people do not have access to essential, safe, affordable surgical care; we aim to address that with the launch of the new Global Surgery Initiative.

¹ The Lancet Commission, Global Surgery 2030
We are championing global health equity and on track with our 2025 Health for Humanity goals

On track

Progress:
In 2022, we are on target to treat, cure or protect more than 330 million people in LMICs
At the heart of this impact is collaboration with more than 100 partners

Partners:

Through the 2025 Health for Humanity goals championing global health equity, we are supporting SDGs:
Global community impact

Lauren Moore
Vice President, Global Community Impact
Established the J&J Center for Health Worker Innovation
Reaching more than 731,000 health workers
Partnered with UNICEF and VillageReach
5-year, $100M commitment for Our Race to Health Equity
We’re proud to focus on strengthening health systems and providing access to quality care for everyone.